Vimta Labs Q1 FY27 Earnings Call — Analysis (NSE: VIMTALABS)
Vimta Labs reports steady Q1FY27 with 13.7% YoY revenue growth and secures first Biologics order, marking entry into high-growth life sciences CRAD
The take
Q1FY27 Total Income ₹112.9 Cr ( +13.7% YoY ) . New guidance — FY27 fy27 capex ₹80 Cr . New story: Biologics entry as new growth vector .
Results
Total income ₹112.9 Cr +13.7% YoY; EBITDA ₹41.1 Cr +16% YoY; EBITDA margin 36.4%; PAT ₹21.0 Cr +11.4% YoY
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total Income | ₹112.9 Cr | +13.7% | yoy · Q1FY27 |
| EBITDA | ₹41.1 Cr | +16% | yoy · Q1FY27 |
| EBITDA Margin | 36.4% | yoy · Q1FY27 · Management stated margins improved on a YoY basis | |
| PAT | ₹21.0 Cr | +11.4% | yoy · Q1FY27 |
| PAT Margin | 18.6% | point_in_time · Q1FY27 | |
| Cash and Equivalents | ₹62.8 Cr | point_in_time · Q1FY27 · As of June 30, 2026 | |
| FY27 Capex Budget | ~₹80 Cr | point_in_time · FY27 · Includes ₹10 Cr for Biologics |
Guidance
FY27 aspirational revenue growth of 20-25% maintained; FY27 capex guided at ~₹80 Cr; Biologics expected to contribute meaningfully from FY29
What management committed to
- Vimta Labs plans to spend approximately INR80 crores on capex in FY27. — INR80 crores, FY27
- Vimta Labs expects the biologics segment to become a meaningful contributor to revenue and profit from the third year (FY29) onwards. — significant, FY29
- Vimta Labs expects EBITDA margins to not decline further from current levels. — no further decline, FY27
Key themes
Diversified portfolio resilience, Biologics entry
How the narrative shifted
- Biologics entry as new growth vector: First order secured, moving from promise to execution.
- Resilient core testing demand: Pharma contact research and testing delivered consistent performance with strong year-on-year growth and improved enquiry inflow.
- Export expansion and US subsidiary: Export share increased from 38% to 40%.
- Margin sustainability amid cost pressures: Margins improved year-on-year despite cost pressures, showing resilience.
- Capacity ramp and infrastructure leverage: Provided specific occupancy figure (60%).
- Geopolitical uncertainties as headwinds: Impact quantified: 50% of food business exposed to import/export; missed some business.
- Electronics testing turnaround: Added specific tailwind: defense budget increase.
- Clinical research recovery: New thread; previously challenged, now showing signs of recovery.
- Food business domestic offset: New thread; domestic focus mitigating global headwinds.
Operational commentary
- Biologics CRAD facility operationalized and first order secured from a domestic customer, with commercialization begun in Q1
- Pharma contact research and testing services delivered stable sequential performance with strong YoY growth, driven by complex molecule outsourcing trend
- Clinical research operations showing early recovery with healthy enquiry and order inflows after a challenging FY26
- Food testing saw decline in import/export samples due to geopolitical challenges; strategy shifted to domestic market to partially offset impact
- Electronics and electrical testing stable; manpower challenges of prior quarters resolved; new EMI/EMC chamber added and operational
- Enquiry levels improving across domestic and international markets, with increasing size and complexity of opportunities
- Export revenue share at ~40%; U.S. remains the largest export market, primarily pharma services
- Customer retention rate above 90% by count; infrastructure of 200,000 sq ft lab space ~60% occupied, sufficient for 4-5 years
- No active acquisition opportunities; open to inorganic growth but none on the table currently
Analyst Q&A
Q. Are we on track for the ~₹500 Cr revenue goal for this year?
We are on track with respect to our growth momentum and confident the same momentum can be maintained barring the Middle East challenges.
Q. Details on the first Biologics customer (name, size, country) and timeline for conversion of other clients in discussion.
Highly confidential, cannot disclose customer details or size; domestic customer. Conversion timeline depends on the project stage of each client.
Q. Will margins go down further from Q1 levels?
We expect margins will not go down further because we expect business to grow in the coming quarters.
Q. What is the capacity utilization of the new facilities?
We define capacity three-dimensionally (infrastructure, equipment, people). Infrastructure is built for medium term, we have occupied ~60% of 200,000 sq ft and are good for 4-5 years.
Q. When will the Biologics segment become a meaningful contributor to top line and margins?
Not this year; from the third year onwards (FY29) we expect significant contribution.
Q. Is the 20-25% growth aspiration still intact, and was the Q1 miss due to the Middle East crisis?
Yes, 20-25% aspiration is on track. We missed some business due to the crisis; Q4 to Q1 is seasonally challenging, so matching Q4 is a positive sign.
Research and educational content only. Not investment advice.